News | Molecular Imaging | June 24, 2015

Siemens' PETNET Solutions to Offer PET Prostate Tracer for Clinical Trials

Company will manufacture, distribute 68Ga-labelled PSMA for prostate cancer PET imaging research in greater New York City area

Siemens, PETNET Solutions, prostate cancer, PET/CT imaging, tracer, New York

June 24, 2015 - Siemens' PETNET Solutions, a wholly owned subsidiary of Siemens Healthcare, announced it will provide clinical researchers in the greater New York City area with access to gallium-68-labeled prostate-specific membrane antigen (Ga-68 labeled PSMA). This investigational tracer is being studied for prostate cancer imaging using positron emission tomography/computed tomography (PET/CT) in clinical trials throughout the world.

Prostate cancer is the second most frequently diagnosed cancer among men in the United States. An estimated 220,000 men are expected to be diagnosed with the disease this year, with approximately 15,000 in New York state alone. Recent hypotheses regarding the variation and diversity of prostate cancer suggest that all variants should not be treated equally – underscoring a need for expanded classification of the disease through imaging and biopsy methods.

For more information: www.siemens.com

Related Content

New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
A 3-D printed tungsten X-ray system collimator. 3D printed, additive manufacturing for medical imaging.

A 3-D printed tungsten X-ray system collimator. The tungsten alloy powder is printed into the form desired and is laser fused so it can be machined and finished. Previously, making collimators from Tungsten was labor intensive because it required working with sheets of the metal to create the collimator matrix. 

Feature | Medical 3-D Printing | April 29, 2019 | By Steve Jeffery
In ...
Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
Improving Molecular Imaging Using a Deep Learning Approach
News | Nuclear Imaging | March 21, 2019
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed...
Houston Methodist Hospital Acquires Focal One High-Intensity Focused Ultrasound System
News | Focused Ultrasound Therapy | March 19, 2019
EDAP TMS SA announced that Houston Methodist Hospital, one of the first hospitals in the U.S. to offer Ablatherm...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...